Under the contract, the company will provide operations and technical support to the NCI in basic research, translational R&D, and preclinical R&D. It will support more than 300 clinical trials and manage a pilot program of community hospitals in 14 states to bring cancer care to rural, inner-city, and underserved patients.
The company has been providing operations and technical support services to the R&D center in Frederick since 1995, and formed SAIC-Frederick in 2000 to continue the work. SAIC-Frederick employs more than 1,700 scientific, technical, and support personnel, and manages advanced technologies in genomics, proteomics, nanotechnology, optical and electron microscopy, and biomedical computing.
The company also operates two biopharmaceutical manufacturing facilities. One for NCI and the other for the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center.
Charles Koontz, group president at SAIC, said: We appreciate the confidence NCI has shown in SAIC over the past 13 years and look forward to continuing our work to help deliver preventive, diagnostic, and therapeutic products to cancer patients.
The contract follows the six-year $49m deal the company won from the US Air Force Research Laboratory (AFRL) Directed Energy Directorate, High Power Microwave (HPM) Division, to support high energy research and applications. It also won an 11-month $212m IT services contract extension from NASA.
